Scarica l'app Stockscreener
10.04
2.32%
-0.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Precedente Chiudi:
$10.29
Aprire:
$10.29
Volume 24 ore:
2.33M
Relative Volume:
0.59
Capitalizzazione di mercato:
$2.86B
Reddito:
-
Utile/perdita netta:
$-125.04M
Rapporto P/E:
-12.24
EPS:
-0.82
Flusso di cassa netto:
$-122.99M
1 W Prestazione:
+4.48%
1M Prestazione:
+196.49%
6M Prestazione:
+487.78%
1 anno Prestazione:
+405.08%
Intervallo 1D:
$10.03
$10.48
Intervallo di 1 settimana:
$8.77
$10.67
Portata 52W:
$1.01
$10.67
Erasca Inc Stock (ERAS) Company Profile
Nome
Erasca Inc
Settore
Industria
Telefono
(858) 465-6511
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO
Confronta ERAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
10.06 | 2.92B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | Jefferies | Buy |
| 2024-03-11 | Iniziato | CapitalOne | Overweight |
| 2024-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-30 | Iniziato | Mizuho | Buy |
| 2023-02-24 | Iniziato | Goldman | Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Erasca Inc Borsa (ERAS) Ultime notizie
Erasca stock hits 52-week high at 10.46 USD By Investing.com - Investing.com Nigeria
Erasca Announces Major Underwritten Public Equity Offering - TipRanks
Erasca, Inc. Announces Upsized Public Offering of Common Stock - TradingView — Track All Markets
Erasca raises $225M to sharpen RAS oncology focus - BioWorld MedTech
Latham & Watkins Advises Erasca in Upsized US$225 Million Offering of Common Stock - Latham & Watkins LLP
Erasca prices $225M stock offering at $10 per share - MSN
A trio of biotechs targets $500M+ offerings - Endpoints News
Erasca stock hits 52-week high at 10.46 USD - Investing.com
Top 2 Tech Stocks That Are Ticking Portfolio Bombs - Benzinga
Erasca Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Erasca, Inc. Announces Pricing of $225 Million Public Offering of Common Stock - Quiver Quantitative
Cancer drug developer Erasca raises $225M in stock sale - Stock Titan
Erasca Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewswire Inc.
Top 2 Industrials Stocks That May Collapse In Q1 - Benzinga
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Erasca plans to raise $150 million in public stock offering By Investing.com - Investing.com Nigeria
Erasca Announces $150 Million Public Offering; Stock Down - Nasdaq
Erasca Stock Pre-Market (-8.3%) : Announces $150M Public Stock Offering - Trefis
Erasca plans $150M public stock offering - MSN
Erasca stock falls after announcing $150 million public offering - Investing.com
Erasca announces proposed public offering of $150 million of common stock - marketscreener.com
Erasca (ERAS) Stock Slides After The Bell: Here's Why - Benzinga
Erasca (ERAS) Announces $150M Public Offering to Fund Cancer Research - Intellectia AI
Erasca reports preliminary year-end cash and securities of $341.8 million - Investing.com
Erasca, Inc. Announces Proposed Public Offering of $150 Million in Common Stock - Quiver Quantitative
Erasca Announces Proposed Public Offering of $150 Million of Common Stock - The Manila Times
Cancer drug developer Erasca plans $150M stock sale to fund R&D - Stock Titan
Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade - Finviz
Erasca (ERAS) touches 3-year high as 4 analysts go bullish; gets 267% PT hike - MSN
Do Early ERAS-0015 Data Reframe Erasca’s (ERAS) Ambitions in RAS-Targeted Oncology? - simplywall.st
Erasca stock surges 42% in a week: Here's what you should know - MSN
Erasca (ERAS) Valuation Comes Into Focus After Early ERAS-0015 Data At JP Morgan Healthcare Conference - simplywall.st
Erasca Offers $7.50 Put Option, Attracting Investor Interest - Intellectia AI
Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike - Finviz
Erasca price target raised to $11 from $5 at Piper Sandler - TipRanks
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Finviz
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - PR Newswire
HC Wainwright Has Strong Estimate for Erasca FY2027 Earnings - Defense World
Winners Losers: What is AXIS Capital Holdings Limiteds debt to equity ratioAnalyst Downgrade & Fast Gain Stock Tips - baoquankhu1.vn
Assessing Erasca (ERAS) Valuation After Encouraging Early ERAS-0015 Data At JP Morgan Conference - Yahoo Finance
Erasca Rallies Amid Acquisition Talks and Positive Price Target Revisions - StocksToTrade
Clear Street Elevates Erasca: Price Target Stands Tall at $11 - timothysykes.com
FY2027 Earnings Forecast for Erasca Issued By HC Wainwright - MarketBeat
Erasca (ERAS) Is Up 60.7% After Early ERAS-0015 Data Highlights Pan-RAS Franchise Ambitions - Yahoo Finance
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - Insider Monkey
10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs - Insider Monkey
Erasca stock hits 52-week high at 8.33 USD By Investing.com - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Trading Up 7.7% Following Analyst Upgrade - Defense World
Erasca (ERAS) Price Target Increased by 30.91% to 6.53 - Nasdaq
Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data - TechStock²
Erasca stock hits 52-week high at 8.33 USD - Investing.com
Erasca Inc Azioni (ERAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):